Immunohistochemical studies have shown E-cadherin antibody to be expressed in breast ductal carcinoma with loss of expression in lobular carcinoma. As a result, mouse monoclonal anti-E-cadherin [HECD-1] has been used by pathologists to differentiate between ductal and lobular carcinomas of the breast, with currently published sensitivity and specificity of approximately 90%. A rabbit monoclonal E-cadherin antibody may combine the best properties of both mouse monoclonal antibodies and rabbit antisera.
|Download Data Sheet
|Download RUO Data Sheet for International
|Download SDS Sheet
Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.
1. de Deus Moura R, et al. Immunohistochemistry Applied to the Differential
Diagnosis Between Ductal and Lobular Carcinoma of the Breast. Appl
Immuohistochem Mol Morphol. 2012 May 16 Epub ahead of print.
2. Dabbs DJ, Bhargava R, Chivukula M. Lobular Versus Ductal Breast Neoplasms:
The Diagnostic Utility of P120 Catenin. Am J Surg Path. 2007;31:427-437.
3. Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH. The role of
immunohistochemistry in the differential diagnosis of breast lesions. Pathology. 2009
4. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22,
Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
5. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.